In what seems a significant step forward in pain management, the US Food and Drug Administration has approved a new non-opioid painkiller for treating short-term pain in adults. Veuer’s Maria Mercedes Galuppo has the story.
Category
🗞
NewsTranscript
00:00In what seems a significant step forward in pain management,
00:04the U.S. Food and Drug Administration has approved a new non-opioid painkiller
00:09for treating short-term pain in adults.
00:11The drug, Cicetrogene branded as Gernovax,
00:14works by targeting pain signals before they reach the brain,
00:17offering relief for moderate to severe pain
00:20without the addictive potential of opioids.
00:22Its maker, Vertex Pharmaceuticals,
00:25says it marks a breakthrough in treating pain
00:27while addressing the ongoing opioid crisis.
00:30The FDA's approval comes after successful clinical trials
00:34showing Gernovax reduced pain following surgery.
00:37This approval is hailed as an important milestone in acute pain management,
00:41especially as the U.S. continues to battle a widespread opioid addiction crisis.
00:46According to the CDC,
00:48nearly 82,000 opioid-involved overdose deaths occurred in 2022 alone.
00:54The BBC reports Gernovax will be priced at $15.50 per capsule,
00:59though it remains unclear whether the drug is safe and effective for children.